Skip to main content
Journal cover image

Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.

Publication ,  Journal Article
Sun, L; Moul, JW; Hotaling, JM; Rampersaud, E; Dahm, P; Robertson, C; Fitzsimons, N; Albala, D; Polascik, TJ
Published in: BJU Int
April 2007

OBJECTIVE: To identify threshold values of prostate-specific antigen (PSA) levels and PSA velocity (PSAV) to optimize the assessment of the risk of prostate cancer in young men, as prostate cancer is detected increasingly in men aged <50 years. PATIENTS AND METHODS: Data for a group of 12 078 men, including 1622 with prostate cancer, were retrieved from the Duke Prostate Center Database. Based on the latest date for a PSA assay, these men were divided into two age groups of <50 and >/= 50 years, with 904 and 11 174 men in each group, respectively. Receiver operating characteristic curves (ROC) of PSA and PSAV were calculated and the cancer risk was assessed. RESULTS: The prevalence of prostate cancer was 4.4% (40 men) for men aged <50 years and 14.2% (1582 men) for men aged >/= 50 years. For the group with cancer the median PSA in men aged <50 years was significantly lower than that in men aged >/= 50 (1.3 vs 6.3 ng/mL, P < 0.001). ROC curves of PSA and PSAV showed a breakpoint at a PSA level of 2.3 ng/mL and a PSAV of 0.60 ng/mL/year for men aged <50 years. Both the sensitivity and specificity in the younger group at a PSA level of 2.5 ng/mL were higher than in the older group. CONCLUSIONS: In men aged <50 years the operating characteristics of PSA are more sensitive and specific than in older men. Diagnostic PSA levels in men aged <50 years are significantly lower than suggested by guidelines. Using a 2.0-2.5 ng/mL PSA level threshold for biopsy in men aged <50 years and a PSAV threshold lower than the traditional 0.75 ng/mL/year is reasonable in contemporary practice. Further studies are warranted to validate these thresholds.

Duke Scholars

Published In

BJU Int

DOI

ISSN

1464-4096

Publication Date

April 2007

Volume

99

Issue

4

Start / End Page

753 / 757

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Sensitivity and Specificity
  • Risk Factors
  • ROC Curve
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Predictive Value of Tests
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sun, L., Moul, J. W., Hotaling, J. M., Rampersaud, E., Dahm, P., Robertson, C., … Polascik, T. J. (2007). Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int, 99(4), 753–757. https://doi.org/10.1111/j.1464-410X.2006.06682.x
Sun, Leon, Judd W. Moul, James M. Hotaling, Edward Rampersaud, Phillipp Dahm, Cary Robertson, Nicholas Fitzsimons, David Albala, and Thomas J. Polascik. “Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.BJU Int 99, no. 4 (April 2007): 753–57. https://doi.org/10.1111/j.1464-410X.2006.06682.x.
Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, et al. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int. 2007 Apr;99(4):753–7.
Sun, Leon, et al. “Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.BJU Int, vol. 99, no. 4, Apr. 2007, pp. 753–57. Pubmed, doi:10.1111/j.1464-410X.2006.06682.x.
Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, Fitzsimons N, Albala D, Polascik TJ. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int. 2007 Apr;99(4):753–757.
Journal cover image

Published In

BJU Int

DOI

ISSN

1464-4096

Publication Date

April 2007

Volume

99

Issue

4

Start / End Page

753 / 757

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Sensitivity and Specificity
  • Risk Factors
  • ROC Curve
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Predictive Value of Tests
  • Middle Aged
  • Male
  • Humans